Moxaclav 250 mg+125 mg (Tablet)

Indications

• Short-term treatment of bacterial infections in upper and lower respiratory tract, genito-urinary tract, skin, soft tissue, bone, joint, and other infections

Composition

• 375 mg tablet with Amoxicillin 250 mg and Clavulanic Acid 125 mg
• 625 mg tablet with Amoxicillin 500 mg and Clavulanic Acid 125 mg
• 1 gm tablet with Amoxicillin 875 mg and Clavulanic Acid 125 mg
• Powder for Suspension with Amoxicillin 125 mg and Clavulanic Acid 31.25 mg
• Powder for Suspension (Forte) with Amoxicillin 400 mg and Clavulanic Acid 57.5 mg
• 1.2 gm Injection with Amoxicillin Sodium 1 gm and Clavulanate Potassium 200 mg
• 0.6 gm injection with Amoxicillin Sodium 500 mg and Clavulanate Potassium 100 mg

Pharmacology

• Bactericidal activity against Gram-positive & Gram-negative microorganisms
• Broad spectrum of activity
• Inactivation of beta-lactamase enzymes
• Optimized absorption with meal
• Peak serum levels occur one hour after oral administration

Dosage

• Different dosages for adults and children based on severity of infection
• Varied recommended daily dosage for different age groups and infection types

Administration

• Oral dosage form can be taken without regard to meals
• IV injection over 2 minutes or slow intravenous infusion over 30 minutes
• Reconstituted vial must be used within 20 minutes

Interaction

• Prolongation of bleeding time and prothrombin time reported
• Reduced efficacy of oral contraceptives
• Potential allergic skin reactions with allopurinol use

Contraindications

• History of Penicillin hypersensitivity
• Cross-sensitivity with other beta-lactam antibiotics
• Previous history of Co-amoxiclav or Penicillin-associated cholestatic jaundice

Side Effects

• Uncommon and mild gastrointestinal side effects
• Rare cases of hepatitis, cholestatic jaundice, urticarial and erythematous rashes
• Reported cases of angioedema and anaphylaxis

Pregnancy & Lactation

• No teratogenic effects observed in animal studies
• Limited human use in pregnancy with no untoward effects reported
• Trace quantities detected in breast milk

Precautions & Warnings

• Use with care in patients on anticoagulation therapy or with severe hepatic dysfunction
• Dosage adjustment for patients with renal impairment
• Adequate fluid intake and urinary output maintenance for high dose administration

Use in Special Populations

• Dosage adjustment for patients with renal or hepatic impairment

Overdose Effects

• Unlikely to occur
• Possible gastrointestinal symptoms and fluid/electrolyte imbalances
• Can be removed by haemodialysis if necessary

Therapeutic Class

• Broad spectrum penicillins

Reconstitution

• IV injection reconstitution with Water for Injection BP
• Not to be mixed with certain solutions or fluids
• Can be injected into infusion fluids containing glucose, bicarbonate, and dextran over 3-4 minutes

Storage Conditions

• Below 25°C, protected from light and moisture
• Reconstituted suspension to be kept in the refrigerator and used within 7 days
• Reconstituted vial to be used within 20 minutes

Related Brands

• Co-Clav (125 mg+31.25 mg)/5 ml (Powder for Suspension) - ad-din-pharmaceuticals-ltd
• Co-Clav 500 mg+125 mg (Tablet) - ad-din-pharmaceuticals-ltd
• Mimoxclav 500 mg+125 mg (Tablet) - albion-laboratories-limited
• Fortimox 500 mg+125 mg (Tablet) - kumudini-pharma-ltd
• Fimoxyclav ES (600 mg+42.9 mg)/5 ml (Powder for Suspension) - synovia-pharma-plc